Pentadeca Arginate vs TB-500

Side-by-side comparison of Pentadeca Arginate, TB-500 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Pentadeca Arginate Pentadeca Arginate (PDA) — BPC-157 Arginine Variant Recovery TB-500 Thymosin Beta-4 Synthetic Analogue Recovery
Basics
Molecular type Pentadecapeptide Arginine AnalogueThymic Peptide Analogue
Amino acids 1543
Molecular weight 1,476.6 Da4,921 Da
Half-life ~4–6 hrs (estimated)Long-acting (days)
Route(s) Subcutaneous, Intramuscular, Oral (research)Subcutaneous, Intramuscular
Mechanism & Research
Primary mechanism PDA shares BPC-157's primary mechanism of action: nitric oxide (NO) synthase upregulation, VEGFR2-mediated angiogenesis, and connective tissue repair signalling. The arginine modification may further amplify NO pathway a… TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical …
Research status Research Compound Research Compound
Evidence summary PDA is a newer research compound with a smaller published evidence base than BPC-157. Most researchers extrapolate from BPC-157's extensive preclinical data given the structural and mechanistic similarity. Direct compara… TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been …
Protocol & Dosing
Typical dose 200–500 mcg per injection5–10 mg per injection
Frequency Once or twice daily2x per week (loading), then weekly
Duration 4–12 weeks4–8 weeks
Timing Near injury site when possible; any timeNo specific timing requirement
Safety
Common side effects
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
  • Injection site reaction
  • Mild fatigue (transient)
  • Headache
  • Lethargy in first days
Contraindications
  • Active malignancy (angiogenesis concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
  • Active cancer (angiogenic activity)
  • Pregnancy
  • Platelet disorders or anticoagulant use
Anti-doping Prohibited (WADA S0) Prohibited (WADA S2)
Deeper reading
Related peptides BPC-157, TB-500, GHK-Cu BPC-157, GHK-Cu, Thymosin Alpha-1
Full profile Read full Pentadeca Arginate profile → Read full TB-500 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.